Target Information

Target General Infomation
Target ID
T57001
Former ID
TTDR00892
Target Name
Cell surface A33 antigen
Gene Name
GPA33
Synonyms
A33 antigen; A33 cognate antigen; GPA33
Target Type
Clinical Trial
Disease Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Function
May play a role in cell-cell recognition and signaling.
BioChemical Class
Immunoglobulin
UniProt ID
Q99795
Sequence
MVGKMWPVLWTLCAVRVTVDAISVETPQDVLRASQGKSVTLPCTYHTSTSSREGLIQWDK
LLLTHTERVVIWPFSNKNYIHGELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVS
LMSDLEGNTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNI
LNQEQPLAQPASGQPVSLKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVG
IAVGVVAALIIIGIIIYCCCCRGKDDNTEDKEDARPNREAYEEPPEQLRELSREREEEDD
YRQEEQRSTGRESPDHLDQ
Drugs and Mode of Action
Drug(s) KRN-330 Drug Info Phase 1/2 Colorectal cancer [532728]
HuA33 Drug Info Phase 1 Colorectal cancer [521702], [527624]
MGD007 Drug Info Phase 1 Colorectal cancer [889404]
Radiolabelled-huA33 Drug Info Phase 1 Colorectal cancer [521801]
Modulator MGD007 Drug Info [889442]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
References
Ref 521702ClinicalTrials.gov (NCT00199797) Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 521801ClinicalTrials.gov (NCT00291486) Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 527624Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005 Jul 1;11(13):4818-26.
Ref 532728Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
Ref 889404ClinicalTrials.gov (NCT02248805) Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
Ref 531562(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80.
Ref 532728Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
Ref 889442Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.